Sandoz Group AG (SDZNY)
PNK: SDZNY
· Real-Time Price · USD
43.08
-0.30 (-0.69%)
At close: May 01, 2025, 3:59 PM
Company Description
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide.
It develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties.
It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics.
The company was founded in 1886 and is headquartered in Rotkreuz, Switzerland.
Sandoz Group AG
| Country | CH |
| IPO Date | Oct 4, 2023 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 22,049 |
| CEO | Richard Saynor |
Contact Details
Address: Suurstoffi 14 Rotkreuz, CH | |
| Website | https://www.sandoz.com |
Stock Details
| Ticker Symbol | SDZNY |
| Exchange | PNK |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | n/a |
| CUSIP Number | 799926100 |
| ISIN Number | US7999261008 |
| Employer ID | - |
| SIC Code | n/a |
Key Executives
| Name | Position |
|---|---|
| Richard Saynor | Chief Executive Officer |
| Asaf Gal | Chief Technology Officer |
| Remco J. Steenbergen | Chief Financial Officer |
| Tripti Jha | Chief People Officer |
| Claire D'Abreu-Hayling | Chief Scientific Officer |
| Dr. Glenn A. Gerecke Ph.D. | Chief Manufacturing & Supply Officer |
| Ingrid Sollerer | General Counsel & Chief Compliance Officer |
| Keren Haruvi | President of North America |
| Laurent de Weck | Head Investor Relations |
| Rebecca Guntern | Chief Commercial Officer |